Ktx-1001, a potent, selective MMSET/NSD2 inhibitor, enhances immunomodulatory and immune-directed therapies in preclinical models of multiple myeloma
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: Cambridge Public School, University of Oxford
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417014434
Cites:
Cited by:
Related to: